Jad Othman News Today

MRD-positive patients in first complete remission after induction therapy had a survival benefit after transplant; however, that benefit did not extend to MRD-negative patients after transplant.

Molecular minimal residual disease status may offer clues as to which patients with acute monocytic leukemia will benefit from certain therapies.

No advantage for MRD-negative patients in first remission after induction, regardless of <em>FLT3</em> ITD

The presence of molecular minimal residual disease following induction chemotherapy can be used to determine patients with NPM1-mutated acute myeloid leukemia who may benefit from allogeneic transplant in first remission, including those with FLT3 ITD–mutated disease.

But trial detects 'meaningful benefit' when it comes to relapse, editorialists say